The relation between *Chlamydia pneumoniae* and atherosclerosis

A causative role of infection in the pathogenesis of atherosclerosis was first proposed in 1908 by Sir William Osler.\(^1\) Although originally this view was not widely accepted, there is now renewed interest in the contributions made by common chronic infections to the pathogenesis and progression of coronary artery disease (CAD). The modern "response to injury" model of atherosclerosis acknowledges that infection may initiate and perpetuate endothelial damage\(^2\) but the contribution of other mechanisms—metabolic, inflammatory, or haemostatic—also needs to be considered.

The latest infective agent to be implicated in atherosclerosis is *Chlamydia pneumoniae*, a Gram negative obligate respiratory pathogen. *C. pneumoniae* is a common cause of bronchitis and pneumonia, but infection is usually subclinical and follows a benign course. Up to 60% of the population have serological evidence of previous infection and individuals are probably infected several times throughout their lives or harbour chronic infection. Because culture of the organism is difficult, confirmation of infection often requires a systemic antibody response to be identified.\(^3\)

**Sero-epidemiological studies**

In 1988 a Finnish case-control study showed that after an acute myocardial infarction (MI) most patients (68%) developed a significant antibody response against an epitope of *Chlamydia* lipopolysaccharide (LPS), present in only 3% of a control group and absent in patients with chronic CAD.\(^4\) Also, stable raised IgG and IgA antibody titres against *C. pneumoniae* (measured by a microimmunofluorescence assay) were significantly higher in the cardiac patients than in the controls. It was suggested that acute MI might be associated with an exacerbation of chronic *C. pneumoniae* infection.

Further support for a causative role was provided by investigating the relation between *C. pneumoniae* antibody titre and subsequent development of CAD in a nested case-control study of sera collected prospectively from the Helsinki Heart Study.\(^5\) Raised IgA titres against *C. pneumoniae* and the presence of immune-complexes containing *C. pneumoniae* LPS antigen were associated with an increased risk of developing a cardiac event six months later (odds ratios 2.3, 95% confidence interval 1.3 to 5.2). These associations were independent of age, hypertension, and smoking.

In Seattle, USA, investigators showed that in patients undergoing coronary angiography, an increased IgG titre against *C. pneumoniae* (a marker of previous or chronic *C. pneumoniae* infection) was associated with a twofold increase in angiographically detectable CAD.\(^6\) Additionally, our group has recently shown a powerful and independent association between seropositivity to *C. pneumoniae* (IgG > 1/64) and prevalent CAD in a community cross-sectional survey.\(^7\)

Serological studies can be criticised in terms of the controls they used, their borderline statistical significances, and their arbitrarily selected *C. pneumoniae* titre cut-offs for seropositivity. Whether an increased antibody titre is a reliable indicator of underlying *C. pneumoniae* infection or simply a reflection of antigenic cross-reactivity, also remains to be resolved. Nevertheless, several laboratories using different techniques and studying patients in different stages of coronary heart disease, have found a consistent association found between disease and *C. pneumoniae* antibody titres or immune-complexes to *C. pneumoniae*.

**Evidence from direct plaque examination**

*C. pneumoniae* was detected by both the polymerase chain reaction (PCR) and immunohistochemical techniques within coronary atheroma of necropsy specimens from South Africans.\(^8\) Of 36 subjects (aged 30–83 years) dying of non-cardiac causes, the organisms were detected in 20 (56%). *C. pneumoniae* was identified within macrophages, the lipid-rich core of atheromatous plaques, and in smooth muscle cells but not in normal tissue adjacent to the sclerotic lesions or in normal coronary arteries from 11 control patients. Lately, similar diagnostic methods detected *C. pneumoniae* in atherectomy specimens from patients with angina\(^9\) and from atheromatous arteries in patients with other vascular diseases.\(^10\)

**Possible mechanisms of damage**

It remains unclear how *C. pneumoniae* enters atheromatous plaques and whether it has a direct causal role in the atherosclerotic process. *C. pneumoniae* organisms can replicate within alveolar macrophages\(^1\) and after pulmonary infection may easily gain access to the circulation to spread systemically by being carried by monocytes and macrophages. The organism has been shown to have a ubiquitous extrapulmonary distribution—so far it has been found in arthritic joints\(^12\) and cerebrospinal fluid\(^13\) in addition to atheromatous arteries.\(^8,10\) The consequences of *C. pneumoniae* uptake by macrophages and the mechanisms of damage at the site of the coronary artery remain unknown but there are several possibilities. Firstly, the organism may simply reside in the macrophage without causing any deleterious effects and any association may be purely coincidental (a secondary passenger). Secondly, chronic macrophage infection may contribute to local inflammation and development of atheromatous plaque. This process may be analogous to the pathogenesis of trachoma, where the closely related *Chlamydia trachomatis* causes blindness as a result of fibrosis which follows conjunctival infiltration by macrophages and lymphocytes.\(^14\) Fibrosis may develop many years after the original infection and represent a hypersensitivity reaction rather than direct effects of the organism itself. Thirdly, *C. pneumoniae* infection may induce a chronic immune activation mediated by cytokines such as IL-1, IL-6, and TNF-alpha that contribute to direct chronic endothelial cell damage or stimulate the synthesis of acute phase proteins such as fibrinogen\(^13\) and C-reactive protein.\(^15\) It is of interest that a
57 kDa chlamydial heat shock protein (HSP) has been identified and which has close homology with mycobacterial HSP (linked with atherosclerosis\(^2\)) and immune cross-reactivity could occur. Finally, because \textit{C pneumoniae} titres show a weak correlation with important procoagulants such as plasma fibrinogen and factor VIIa concentration\(^1\) another possibility is that chronic infection leads to an enhanced procoagulant state with increased risk of coronary thrombosis. This could be mediated by monocytederived procoagulants such as tissue factor,\(^3\) by circulating immune-complexes, or by monocyte-derived cytokines.

**Conclusion**

A direct role for chronic chlamydial infection in the pathogenesis of CAD is plausible but has yet to be verified. Evidence in support of causation rather than association will only come from prospective vaccination and antibiotic eradication trials. \textit{C pneumoniae} infection is common and treatable. If the eradication trials that are now currently underway show conclusive benefit, then Sir William Osler’s original hypothesis\(^1\) will have been supported and antibiotics may play a part in combating the epidemic of coronary artery disease.

**SANDEEP GUPTA**

**EDWARD W LEATHAM**

Department of Cardiological Sciences, St George’s Hospital Medical School, London SW17 ORE

The relation between Chlamydia pneumoniae and atherosclerosis.

S. Gupta and E. W. Leatham

Heart 1997 77: 7-8
doi: 10.1136/hrt.77.1.7

Updated information and services can be found at:
http://heart.bmj.com/content/77/1/7.citation

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Articles on similar topics can be found in the following collections

- Drugs: cardiovascular system (8842)
- Acute coronary syndromes (2742)
- Clinical diagnostic tests (4779)
- Epidemiology (3752)
- Hypertension (3006)
- Tobacco use (635)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/